IRulya Therapeutics Inc(QNCX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -125.6 | Insider Own | 3.52% | Shs Outstand | 1.0M | Perf Week | 8.66% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.0M | Perf Month | 9.56% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -1.39 | Inst Own | 33.89% | Short Float | 6.12% | Perf Quarter | 83.94% |
| Income | -0.09B | P/S | - | EPS this Y | - | Inst Trans | -4.12% | Short Ratio | 2.1 | Perf Half Y | 16.4% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 74.07% | ROA | -76.68% | Short Interest | 0.06M | Perf YTD | -95.26% |
| Book/sh | -34.73 | P/C | 0.28 | EPS past 3/5Y | -2.82% 8.64% | ROE | -153.84% | 52W High | -96.51% ($909.98) | Perf Year | -92.22% |
| Cash/sh | 114.04 | P/FCF | - | Sales past 3/5Y | - | ROIC | -85.24% | 52W Low | 110.13% ($15.10) | Perf 3Y | -85.44% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.02% | Gross Margin | - | Volatility(W/M) | 10.35% 9.14% | Perf 5Y | -99.82% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.74 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.52 | EPS Q/Q | 82.1% | Profit Margin | - | RSI (14) | 56.91 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.52 | Sales Q/Q | - | SMA20 | 7.86% ($29.42) | Beta | 1.8 | Target Price | $74.44 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | 4.34% ($30.41) | Rel Volume | 4.85 | Prev Close | $29.36 |
| Employees | 38 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 56.07% - | SMA200 | -67.88% ($98.79) | Avg Volume(3M) | 0.03M | Price | $31.73 |
| IPO | 2019/5/9 | Option/Short | No/Yes | Trades | 1727 | Volume | 138,744 | Change | 8.07% |
🧬 Quince Therapeutics is a late-stage biotech company focused on rare diseases that has developed a proprietary <strong>AIDE (Autologous Intracellular Drug Encapsulation)</strong> platform, which encapsulates drugs within a patient's own red blood cells. Its lead candidate is <strong>eDSP (EryDex)</strong>, a red blood cell–based formulation of dexamethasone, developed to target <strong>Ataxia-Telangiectasia (A-T)</strong>, a rare pediatric neurological disorder. It is a nano-cap biotech listed on Nasdaq ().
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded more than usual. That is 485% of its average volume.
QNCX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 33.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #444 of 598 in the industry
Based on market cap of $32M.
ALDX#441 Aldeyra Therapeutics Inc $34M PER - 
IRLA#442 IRulya Therapeutics Inc $34M PER - 
IBO#443 Impact BioMedical Inc $32M PER - QNCX#444 IRulya Therapeutics Inc $32M PER - 
ACET#444 Adicet Bio Inc $32M PER - 
FAQ
What kind of company is QNCX?
QNCX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of QNCX?
The market cap of QNCX is approximately $32M, ranking 5,117 within its sector.
What is the 52-week high and low for QNCX?
QNCX has recorded a 52-week high of $909.98 and a low of $15.10.
